Share: Facebook Twitter LinkedIn
Activity Provided By:


Individualized Strategies for Relapsed/Refractory Multiple Myeloma: Navigating Complexity with BCMA-Targeted and Novel Bispecific Antibodies

Access Activity

Overview / Abstract:

The expanding armamentarium of therapies for R/R MM shifts therapy selection from an algorithmic approach to an individualized strategy that requires consideration of the nature of relapse, prior therapies, treatment-related toxicities, as well as patient comorbidities and preferences. With the introduction of novel bispecific antibodies, specialists must learn how to optimally sequence these therapies and manage adverse events. To help clinicians navigate this complexity, individualized education is essential to accommodate early career providers, community oncologists, and advanced specialists. The ACHL AdaptEdĀ® platform achieves this by expanding and contracting to accommodate different learning needs to achieve meaningful results.


Dec 22, 2024


Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME


Online, Webinar / Webcast / Video

Credits / Hours

1.25 hours



Presenters / Authors / Faculty

Faiz Anwer, MD, FACP
Associate Professor of Medicine, Multiple Myeloma Program
Hematology, Oncology, Stem Cell Transplantation
Director, Inpatient Lymphoma Myeloma Service
Taussig Cancer Center
Cleveland Clinic
Cleveland, OH

Surbhi Sidana, MD
Assistant Professor of Medicine
Stanford Medicine
Palo Alto, CA

Sponsors / Supporters / Grant Providers

Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Pfizer.

Keywords / Search Terms

ACHL Multiple Myeloma, myeloma, relapsed/refractory, BCMA-directed therapies, GPRC5D, RRMM, RR/MM, targeted therapies, adaptive, personalized treatment, hematology, oncology, hematologist, oncologist, MM therapies, treatment, novel agents, agents, MOA, mechanisms of action, clinical evidence, adverse events, personalized learning, simulated cases, teclistamab, elranatamab, Pfizer, Janssen, Cleveland Clinic, CCF, ACPE, ANCC, AAPA Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map